Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Course of Rehabilitation of Ventilated and Tracheally Cannulated Patients in Neurological-Neurosurgical Early Rehabilitation.

Deutsches Arzteblatt international·2026
Same author

Validation of the SMART-REACH model after stroke and the effect of colchicine by atherosclerotic cardiovascular disease risk category: a secondary analysis of the CONVINCE randomised clinical trial.

European stroke journal·2026
Same author

Guidelines for Neuroprognostication in Critically ill Adults with Acute Ischemic Stroke.

Neurocritical care·2026
Same author

Guidelines for Neuroprognostication in Critically Ill Adults with Status Epilepticus.

Neurocritical care·2026
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Effect of colchicine for secondary prevention according to stroke subtype: A secondary analysis of the CONVINCE randomized trial.

International journal of stroke : official journal of the International Stroke Society·2025
Same journal

Life's essential 8 and its role in cardiovascular health: evolution, evidence, and future directions.

Expert review of cardiovascular therapy·2026
Same journal

Efficacy and safety of clopidogrel and aspirin initiated within 72 hours after mild ischemic stroke or high-risk TIA by sex: a prespecified subgroup analysis of the INSPIRES trial.

Expert review of cardiovascular therapy·2026
Same journal

Approaches to transcatheter aortic valve replacement failure: is more focus on prevention required?

Expert review of cardiovascular therapy·2026
Same journal

Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.

Expert review of cardiovascular therapy·2026
Same journal

Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk.

Expert review of cardiovascular therapy·2026
Same journal

Contemporary approach and key considerations to asymptomatic aortic stenosis treatment.

Expert review of cardiovascular therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Antithrombotic medication for stroke prevention.

Christian Weimar1, Ralph Weber, Hans-Christoph Diener

  • 1Department of Neurology and Stroke Center, University Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany. christian.weimar@uk-essen.de

Expert Review of Cardiovascular Therapy
|October 10, 2009
PubMed
Summary
This summary is machine-generated.

Aspirin and other antiplatelet therapies are key for noncardioembolic stroke prevention. For atrial fibrillation, oral anticoagulation offers superior stroke risk reduction compared to antiplatelet agents.

Related Experiment Videos

Last Updated: Jun 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Stroke remains a leading cause of disability and mortality worldwide.
  • Effective antithrombotic strategies are crucial for secondary stroke prevention.
  • Evolving research continually refines optimal therapeutic approaches.

Purpose of the Study:

  • To provide an updated overview of antithrombotic stroke-prevention strategies.
  • To summarize innovative and clinically relevant studies in medical stroke prevention.
  • To offer expert opinion on selected fields of stroke prevention.

Main Methods:

  • Hand-search of relevant medical journals by study authors.
  • Compilation of a broad summary of innovative and clinically relevant studies.
  • Expert synthesis and summarization of findings for selected areas.

Main Results:

  • Aspirin, clopidogrel, or dipyridamole-aspirin are foundational for noncardioembolic stroke prevention.
  • Potent antiplatelet agents or dual antiplatelet therapy (aspirin plus clopidogrel) reduce ischemic events but increase bleeding risk.
  • Oral anticoagulation is more effective than aspirin or dual antiplatelet therapy for secondary stroke prevention in atrial fibrillation patients.

Conclusions:

  • Established antiplatelet regimens remain cornerstones for noncardioembolic stroke.
  • Balancing efficacy and bleeding risk is critical when intensifying antiplatelet therapy.
  • Oral anticoagulation is the preferred strategy for stroke prevention in atrial fibrillation.